ESSA Pharma 2023 Corporate Presentation - Prostate Cancer Biotech

ESSA Pharma is a biopharmaceutical company focused on developing novel therapies for prostate and androgen-driven cancers. Its lead candidate EPI-7386, a first-in-class oral androgen receptor N-terminal domain inhibitor, is in late-stage development for metastatic castration-resistant prostate cancer as both a monotherapy and in combination with leading antiandrogens. The company is headquartered in South San Francisco and Vancouver with cash runway through 2025.